In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Ampliphi Biosciences (APHB), with a price target of $3.50. The company’s shares closed yesterday at $0.30.
Pantginis said:
“Valuation and risks to price target achievement. We reiterate our Buy rating at the price target of $3.50. We project the following in our clinical NPV model for S. aureus: (1) projected launch in 2021 for bacteremia with a 15% chance of success and $300 million in peak sales; and (2) projected launch in 2022 for prosthetic joint infections with a 10% chance of success and $200 million in peak sales.”
According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -15.3% and a 29.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Checkpoint Therapeutics Inc, and Strata Skin Sciences Inc.
Ampliphi Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $3.50.
See today’s analyst top recommended stocks >>
Based on Ampliphi Biosciences’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $3.05 million. In comparison, last year the company had a GAAP net loss of $779K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AmpliPhi Biosciences Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company was founded in March 1989 and is headquartered in San Diego, CA.
